Bagheri H, Bompart G, Girolami J P, Montastruc J L, Montastruc P
Laboratoire de Pharmacologie Médicale et clinique, INSERM U317, Faculté de Médecine, Toulouse, France.
Fundam Clin Pharmacol. 1992;6(1):17-20. doi: 10.1111/j.1472-8206.1992.tb00089.x.
We have previously reported that the alpha 2-adrenoceptor antagonist yohimbine induced a significant increase in both salivary flow rate and kallikrein output. In order to assess the possible role of the kinin-kallikrein system in the increase in salivary secretion elicited by yohimbine, the effects of aprotinin, an inhibitor of kallikrein activity, were investigated in yohimbine-treated conscious dogs. Aprotinin (at a dose, 5000 IU/kg iv, which reduced both resting and yohimbine-induced increase in kininogenase and amidolytic activities of saliva) which remained inactive alone, failed to modify the increase in salivary volume elicited by yohimbine (0.5 mg/kg iv). These results show that the rise in salivary flow rate observed under alpha 2-adrenoceptor antagonist is not induced by the kinin-kallikrein system. The release of kallikrein into saliva observed after yohimbine is rather the consequence than the cause of the increase in salivary secretion.
我们之前曾报道,α2-肾上腺素能受体拮抗剂育亨宾可显著增加唾液流速和激肽释放酶的分泌量。为了评估激肽-激肽释放酶系统在育亨宾引起的唾液分泌增加中可能发挥的作用,我们研究了激肽释放酶活性抑制剂抑肽酶对育亨宾处理的清醒犬的影响。抑肽酶(静脉注射剂量为5000 IU/kg,可降低静息状态下以及育亨宾诱导的唾液激肽原酶和酰胺水解活性的增加)单独使用时无活性,未能改变育亨宾(静脉注射0.5 mg/kg)引起的唾液量增加。这些结果表明,在α2-肾上腺素能受体拮抗剂作用下观察到的唾液流速增加并非由激肽-激肽释放酶系统诱导。育亨宾后观察到的激肽释放酶释放到唾液中,更像是唾液分泌增加的结果而非原因。